Scientific References

Check out the scientific literature that supports our molecular targets and our synthetic lethal approach.

May 2024

ATR inhibitor, camonsertib, dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)

April 2024

Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas

April 2024

Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma

January 2024

Detection and characterization of DDR reversion alterations in baseline tissue and plasma samples from patients enrolled in the TRESR and ATTACC Phase I clinical trials

October 2023

KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition

We have a number of synthetic lethal therapies in development.